Switching Early Breast Cancer Patients To Exemestane Improves Long-term Survival, Study Finds

New research has found that switching post-menopausal women with early breast cancer to the drug exemestane (Aromasin) after two or three years of tamoxifen rather than keeping them on tamoxifen for five years improves the chance of remaining cancer free and reduces the risk of death for at least the next six years.

Read the whole article on Science Daily

More from Science Daily